# US 2003/0229044 A1 · Use of statins and other immunomodulatory agents in the treatment of autoimmune disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229044 A1
- Document ID: US20030229044A1
- Status: Published application
- Kind: A1
- Application number: 10/404,679
- Filed: 2003-03-31
- Published: 2003-12-11
- Earliest claimed: 2002-03-29
- Inventors: Lawrence Steinman; Hideki Garren
- Web page: https://patentgrep.com/patent/US20030229044A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/2026: {IL-4}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods are provided for the treatment of autoimmune diseases, by co-administering a statin and a second immunomodulaotry agent. The second immunomodulatory agent can be antigen-specific or non-antigen-specific.

## Claims

### Claim 1

A method of treating an autoimmune disease, the method comprising:
co-administering to a patient suffering from the autoimmune disease an effective amount of a statin and an effective amount of an antigen-specific immunomodulatory agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antigen-specific immunomodulatory agent is a self-vector comprising a polynucleotide encoding a self-polypeptide associated with the autoimmune disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein the self-polypeptide is a self-protein or self-peptide.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antigen-specific immunomodulatory agent is a polypeptide.

### Claim 5 (depends on 4)

The method of claim 4, wherein the polypeptide is a protein or peptide.

### Claim 6 (depends on 4)

The method of claim 4, wherein the polypeptide is a derivative polypeptide.

### Claim 7 (depends on 4)

The method of claim 4, wherein the polypeptide comprises a self-polypeptide associated with the disease.

### Claim 8 (depends on 4)

The method of claim 4, wherein the polypeptide comprises amino acids corresponding to an autoantigenic epitope of a self-polypeptide associated with the disease.

### Claim 9 (depends on 8)

The method of claim 8, wherein the amino acids corresponding to the autoantigenic epitope are randomized to form a random copolymer.

### Claim 10 (depends on 9)

The method of claim 9, wherein the random copolymer is a peptide.

### Claim 11 (depends on 8)

The method of claim 8, wherein the amino acids corresponding to the autoantigenic epitope are ordered, the polypeptide thereby comprising an ordered amino acid motif.

### Claim 12 (depends on 11)

The method of claim 11, wherein the autoimmune disease is a demyelinating autoimmune disease and the ordered amino acid motif is [1E2Y3Y4K]n, where n is from 2 to 6.

### Claim 13 (depends on 1)

The method of claim 1, wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, insulin dependent diabetes mellitus (IDDM), rheumatoid arthritis, and autoimmune uveitis.

### Claim 14 (depends on 13)

The method of claim 13, wherein the autoimmune disease is multiple sclerosis.

### Claim 15 (depends on 14)

The method of claim 14, wherein the statin is selected from the group consisting of rosuvastatin, mevastatin, lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, and cerivastatin.

### Claim 16 (depends on 15)

The method of claim 15, wherein the statin is atorvastatin.

### Claim 17 (depends on 2)

The method of claim 2, wherein the polypeptide encoded by the polynucleotide is selected from the group consisting of myelin basic protein (MBP), proteolipid protein (PLP), myelin associated glycoprotein (MAG), cyclic nucleotide phosphodiesterase (CNPase), myelin-associated oligodendrocytic basic protein (MBOP), myelin oligodendrocyte protein (MOG), and alpha-B crystalline.

### Claim 18 (depends on 2)

The method of claim 2, wherein the autoimmune disease is insulin dependent diabetes mellitus (IDDM).

### Claim 19 (depends on 18)

The method of claim 18, wherein the self-polypeptide encoded by the polynucleotide is selected from the group consisting of insulin, insulin B chain, preproinsulin, proinsulin, 65 kDA form of glutamic acid decarboxylase, 67 kDa form of glutamic acid decarboxylase, tyrosine phosphatase IA2 or IA-2b, carboxypeptidase H, a heat shock protein, glima38, 69 kDa form of islet cell antigen, p52, and islet cell glucose transporter (GLUT 2).

### Claim 20 (depends on 19)

The method of claim 19, wherein the self-vector comprises a polynucleotide encoding one self-polypeptide.

### Claim 21 (depends on 20)

The method of claim 20, wherein the self-polypeptide is preproinsulin.

### Claim 22 (depends on 20)

The method of claim 20, wherein the self-polypeptide is insulin B chain 9-23.

### Claim 23 (depends on 2)

The method of claim 2, wherein the autoimmune disease is rheumatoid arthritis.

### Claim 24 (depends on 23)

The method of claim 23, wherein the polypeptide encoded by the polynucleotide is selected from the group consisting of type II collagen; hnRNP A2/RA33; Sa; filaggrin; keratin; cartilage proteins including gp39; collagens type I, III, IV, V, IX, XI; HSP-65/60; RNA polymerase; hnRNP-B1; hnRNP-D; and aldolase A.

### Claim 25 (depends on 2)

The method of claim 2, wherein the autoimmune disease is autoimmune uveitis.

### Claim 26 (depends on 25)

The method of claim 25, wherein the polypeptide encoded by the polynucleotide is selected from the group consisting of S-antigen, interphotoreceptor retinoid binding protein (IRBP), rhodopsin, and recoverin.

### Claim 27

A method for treating an autoimmune disease, the method comprising:
co-administering to a patient suffering from the autoimmune disease an effective amount of a statin and an effective amount of an non-antigen-specific immunomodulatory agent.

### Claim 28 (depends on 27)

The method of claim 27, wherein the non-antigen specific immunomodulatory agent is an immune modulatory sequence.

### Claim 29 (depends on 28)

The method of claim 28, wherein the immune modulatory sequence is selected from the group consisting of
(a) 5′-Purine-Pyrimidine-[X]-[Y]-Pyrimidine-Pyrimidine-3′ and
(b) 5′-Purine-Purine-[X]-[Y]-Pyrimidine-Pyrimidine-3′,
wherein X and Y are any naturally occurring or synthetic nucleotide, except that X and Y cannot be cytosine-guanine.

### Claim 30 (depends on 27)

The method of claim 27, wherein the non-antigen-specific immunomodulatory agent is osteopontin.

### Claim 31 (depends on 27)

The method of claim 27, wherein the non-antigen-specific immunomodulatory agent is a self-vector comprising a polynucleotide encoding ostepontin.

### Claim 32 (depends on 27)

The method of claim 27, wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, insulin dependent diabetes mellitus (IDDM), rheumatoid arthritis, and autoimmune uveitis.

### Claim 33 (depends on 32)

The method of claim 32, wherein the autoimmune disease is multiple sclerosis.

### Claim 34 (depends on 27)

The method of claim 27, wherein the statin is selected from the group consisting of rosuvastatin, mevastatin, lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, and cerivastatin.

### Claim 35 (depends on 34)

The method of claim 34, wherein the statin is atorvastatin.
